IC
SIOX

Ikarian Capital’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Ikarian Capital’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-177,684
Closed -$820K – 260
2020
Q3 		$820K Sell
177,684
-11,200
-6% -$37K 0.06% 131
2020
Q2 		$533K Hold
188,884
– – 0.04% 133
2020
Q1 		$461K Hold
188,884
– – 0.03% 136
2019
Q4 		$967K Buy
+188,884
New +$1.05M 0.16% 81

Other funds holding SIOX

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCA
Sassicaia Capital Advisers Jericho, New York $88.8M AUM 146.47% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Ikarian Capital's SIOX Position: Q4 2020 in Review

Ikarian Capital sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q4 2020, closing a stake of 177,684 shares — an estimated $820K sold.

Ikarian Capital first reported a position in SIOX in Q4 2019 and held it in 4 quarters. The position peaked at $967K in Q4 2019. 62 funds tracked by Wall St. Rank hold SIOX as of Q4 2020.

  • Ikarian Capital reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Ikarian Capital sold 177,684 Sio Gene Therapies Inc. Common Stock shares in Q4 2020, an estimated $820K.
  • Ikarian Capital first reported a position in Sio Gene Therapies Inc. Common Stock in Q4 2019 and held it in 4 quarters.
  • Ikarian Capital's Sio Gene Therapies Inc. Common Stock position peaked at $967K in Q4 2019.
  • 62 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q4 2020.

Based on Ikarian Capital's 13F filing for Q4 2020, filed 12 Feb 2021.